Document is current
Any future updates will be listed below
-
Authors
Escobar, Helena https://orcid.org/0000-0002-8128-7845
Di Francescantonio, Silvia
Smirnova, Julia
Graf, Robin https://orcid.org/0000-0002-5400-9938
Müthel, Stefanie https://orcid.org/0000-0002-3525-8859
Marg, Andreas https://orcid.org/0000-0003-3673-4244
Zhogov, Alexej
Krishna, Supriya
Metzler, Eric
Petkova, Mina
Daumke, Oliver https://orcid.org/0000-0002-6190-1414
Kühn, Ralf https://orcid.org/0000-0003-1694-9803
Spuler, Simone https://orcid.org/0000-0002-0155-1117
-
Funding
Funding for this research was provided by:
Stiftung Gisela Krebs
- License Information
-
More Information
Article History
Received: 15 September 2022
Accepted: 29 November 2024
First Online: 2 January 2025
Competing interests
: Si.S. is an inventor on a technology for primary human muscle stem cell isolation and manufacturing (IP: (DE10 2014 216872), 2015 PCT (WO 2016/030371), granted in EU and US). Si.S. and H.E. are co-inventors on a pending patent application on gene editing of human muscle stem cells (European Patent Office 21 160 696.7). Si.S. is co-founder of MyoPax GmbH and MyoPax Denmark ApS. The remaining authors declare no competing interests.
